CAS No. |
6040-19-3 |
中文名称 |
(R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-二羟基-9-(羟甲基)-4,4,13,14-四甲基-3,11-二氧代-2,3,4,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊二烯并[a]菲-17-基)-6-羟基-2-甲基-5-氧代庚-3-烯-2-基乙酸酯 |
英文名称 |
(R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-9-(hydroxymethyl)-4,4,13,14-tetramethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate |
别名 |
Cucurbitacin A;(10α,23E)-25-(Acetyloxy)-2β,16α,20-trihydroxy-9β-(hydroxymethyl)-19-norlanosta-5,23-diene-3,11,22-trione;2,16,20,25-Tetrahydroxy-9-(hydroxymethyl)-19-norlanosta-5,23-diene-3,11,22-trione 25-acetate;Cucurbitacine A;NSC 94743;Cucurbit A;(2S,4R,9beta,16alpha,23E)-2,16,20-trihydroxy-9-(hydroxymethyl)-10,14-dimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate;19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-, (2β,9β,10α,16α,23E)- |
标准英文名 |
(R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-9-(hydroxymethyl)-4,4,13,14-tetramethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate |
MDL No. |
- |
分子式 |
C32H46O9 |
分子量 |
574.71
|
精确分子量 |
574.31
|
SMILES |
CC(=O)OC(C)(C)/C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C[C@H](O)C(=O)C4(C)C)[C@]3(CO)C(=O)C[C@]12C |
标准SMILES |
CC(=O)OC(C)(C)/C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C[C@H](O)C(=O)C4(C)C)[C@]3(CO)C(=O)C[C@@]21C |
用途 |
Cucurbitacin A is used in the treatment of primary liver cancer. Clinical observations from six hospitals in Shanghai, Beijing, Guangxi, and other regions involving 169 cases showed an overall efficacy rate of 69% and a marked efficacy rate of 39%. Clinical data indicate that, compared with 5-fluorouracil, Cucurbitacin A demonstrates superior performance in alleviating symptoms, relieving hepatic pain, reducing tumor size, prolonging survival, and restoring physical strength, without the typical toxic side effects associated with conventional chemotherapeutic agents. |
InChIKey |
IHTCCHVMPGDDSL-IVNGUWCNSA-N |